Efficacy Study of Oral Sapacitabine to Treat Acute Myeloid Leukemia in Elderly Patients

Not Recruiting

Trial ID: NCT00590187


The objective is to treat elderly AML and MDS patients with sapacitabine.

Official Title

A Randomized Phase 2 Study of Oral Sapacitabine in Elderly Patients With Acute Myeloid Leukemia Previously Untreated or in First Relapse, or Previously Treated Myelodysplastic Syndromes

Stanford Investigator(s)

Caroline Berube
Caroline Berube

Clinical Associate Professor, Medicine - Hematology

Jason Gotlib

Professor of Medicine (Hematology)


Inclusion Criteria:

   - A histologically or pathologically confirmed diagnosis of AML based on WHO
   classification which is previously untreated by systemic therapy or is in first
   relapse after achieving a complete remission to initial induction, consolidation
   and/or maintenance therapy or MDS with IPSS scores of intermediate -2 or higher risk
   risk which has been previously treated with hypomethylating agents

   - Age 70 years or older for AML and 60 years or older for MDS

   - Eastern Cooperative Oncology Group (ECOG) performance status 0-2

   - Adequate renal function defined as serum creatinine equal to or less than 1.5 x upper
   limit of normal (ULN)

   - Adequate liver function defined as total bilirubin or direct bilirubin equal to or
   less than 1.5 x ULN; alanine aminotransferase (ALT or SGPT) equal to or less than 2.5
   x ULN (5 x ULN if tumor has affected the liver)

   - Life expectancy reasonably adequate for evaluating the treatment effect

   - Patient must be able to swallow capsules

   - Patients must be at least 2 weeks from prior systemic therapy, radiation therapy,
   major surgery, or other investigational therapy, and have recovered from clinically
   significant toxicities of these prior treatments

   - All men and women of reproductive potential must agree to practice effective
   contraception for 4 weeks prior to study entry, during the entire study period and for
   one month after the study unless documentation of infertility exists

   - Ability to understand and willingness to sign the informed consent form

Exclusion Criteria:

   - AML is of the sub-type of acute promyelocytic leukemia

   - Having received more than one induction systemic therapy for AML or having received a
   standard dose or high dose ara-C containing regimen for MDS

   - Patients with known central nervous system (CNS) involvement by leukemia

   - Uncontrolled intercurrent illness including, but not limited to ongoing or active
   infection, active cancer(s) other than AML, symptomatic congestive heart failure,
   unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations
   that would limit compliance with study requirements. Patients receiving intravenous
   antibiotics for infections that are under control may be included in this study

   - Known to be HIV-positive


drug: Sapacitabine, Arm A

drug: Sapacitabine, Arm B

drug: Sapacitabine, Arm C

drug: Sapacitabine, Arm D

drug: sapacitabine, Arm E

drug: sapacitabine, Arm F

drug: Sapacitabine, Arm G

drug: Sapacitabine, Arm H

drug: Sapacitabine, Arm I

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Cancer Clinical Trials Office

New Trial Alerts

Receive email alerts when trials open to patients.